EP Patent

EP1165500A1 — Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase

Assigned to Bristol Myers Squibb Pharma Co · Expires 2002-01-02 · 24y expired

What this patent protects

The present application describes novel amides and derivatives thereof of formula (I) or pharmaceutically acceptable salt forms thereof, wherein these compounds are useful as inhibitors of matrix metalloproteinases, TNF-α, and aggrecanase.

USPTO Abstract

The present application describes novel amides and derivatives thereof of formula (I) or pharmaceutically acceptable salt forms thereof, wherein these compounds are useful as inhibitors of matrix metalloproteinases, TNF-α, and aggrecanase.

Drugs covered by this patent

Patent Metadata

Patent number
EP1165500A1
Jurisdiction
EP
Classification
Expires
2002-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Pharma Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.